Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Iressa Re-challenge in Advanced NSCLC EGFR Mutated Patients Who Responded to an EGFR-TKI Used as First-line or Previous Treatment (NVALT 16)

NCT02025218 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.

NCT NCT02025218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02025218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Iressa Re-challenge in Advanced NSCLC EGFR Mutated Patients Who Responded to an EGFR-TKI Used as First-line or Previous Treatment (NVALT 16)
Lead sponsor
Amsterdam UMC, location VUmc
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2014
Completion date
June 30, 2017
Enrollment
21 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer